Constantine S. Tam

29.6k total citations · 6 hit papers
401 papers, 8.8k citations indexed

About

Constantine S. Tam is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Constantine S. Tam has authored 401 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 337 papers in Genetics, 219 papers in Pathology and Forensic Medicine and 96 papers in Hematology. Recurrent topics in Constantine S. Tam's work include Chronic Lymphocytic Leukemia Research (320 papers), Lymphoma Diagnosis and Treatment (216 papers) and Chronic Myeloid Leukemia Treatments (79 papers). Constantine S. Tam is often cited by papers focused on Chronic Lymphocytic Leukemia Research (320 papers), Lymphoma Diagnosis and Treatment (216 papers) and Chronic Myeloid Leukemia Treatments (79 papers). Constantine S. Tam collaborates with scholars based in Australia, United States and Italy. Constantine S. Tam's co-authors include Michael J. Keating, John F. Seymour, William G. Wierda, Hagop M. Kantarjian, David Westerman, Jörge E. Cortes, Susan Lerner, Andrew W. Roberts, Susan O’Brien and Mary Ann Anderson and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Constantine S. Tam

364 papers receiving 8.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

2008 508 citations Constantine S. Tam, William G. Wierda et al. Blood profile →
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

2015 350 citations Constantine S. Tam, William G. Wierda et al. Blood profile →
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

2019 307 citations Jennifer R. Brown, Susan O’Brien et al. profile →
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

2018 276 citations Piers Blombery, Mary Ann Anderson et al. Cancer Discovery profile →
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

2018 274 citations Constantine S. Tam, Mary Ann Anderson et al. profile →
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

2022 124 citations Constantine S. Tam, John N. Allan et al. Blood profile →

Peers

Countries citing papers authored by Constantine S. Tam

Since Specialization

Citations

This map shows the geographic impact of Constantine S. Tam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Constantine S. Tam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Constantine S. Tam more than expected).

Fields of papers citing papers by Constantine S. Tam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Constantine S. Tam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Constantine S. Tam. The network helps show where Constantine S. Tam may publish in the future.

Co-authorship network of co-authors of Constantine S. Tam

This figure shows the co-authorship network connecting the top 25 collaborators of Constantine S. Tam. A scholar is included among the top collaborators of Constantine S. Tam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Constantine S. Tam. Constantine S. Tam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study 2024 ·Blood ·Constantine S. Tam, Anna Maria Frustaci, Fontanet Bijou, (unknown), John F. Seymour, Masa Lasica, Herbert Eradat, (unknown), (unknown), Irina Mocanu, Xiangmei Chen, Kunthel By, (unknown), Daniel O. Persky, Amit Agarwal, Chan Y. Cheah	2
2	Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study 2024 ·Blood ·Meghan C. Thompson, Ricardo Parrondo, Anna Maria Frustaci, John N. Allan, Paolo Ghia, Irina Mocanu, Constantine S. Tam, Judith Trotman, Inhye E. Ahn, Stephan Stilgenbauer, Lydia Scarfò, Xiangmei Chen, Kunthel By, (unknown), Daniel O. Persky, Amit Agarwal, John F. Seymour	14
3	CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies 2024 ·Blood ·Armin Ghobadi, Joseph P. McGuirk, Paul Shaughnessy, Constantine S. Tam, Melanie Allen, Chenyi Pan, Ziliang Li, William B. Stevens, (unknown), Chan Y. Cheah	5
4	Patient-Specific Nanoparticle Targeting in Human Leukemia Blood 2024 ·ACS Nano ·Yi Ju, Shiyao Li, (unknown), Emily H. Pilkington, (unknown), Magdalena Plebanski, Jiwei Cui, Frank Caruso, Kristofer J. Thurecht, Constantine S. Tam, Stephen J. Kent	19
5	Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA). 2024 ·Journal of Clinical Oncology ·Mazyar Shadman, Jennifer R. Brown, (unknown), (unknown), Heather Burnett, Binod Neupane, Rhys Williams, Nicole Lamanna, Susan O’Brien, Alessandra Tedeschi, Constantine S. Tam	1
6	Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study. 2024 ·Journal of Clinical Oncology ·Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wróbel, Nilanjan Ghosh, Mary‐Margaret Keating, Tom van Meerten, Rubén Fernández-Álvarez, Gottfried von Keudell, Catherine Thiéblemont, Frédéric Peyrade, (unknown), Marc Hoffmann, Maoko Naganuma, Edith Szafer‐Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam	4
7	Ocular toxoplasmosis during frontline venetoclax therapy for chronic lymphocytic leukaemia – more than meets the eye 2023 ·SHILAP Revista de lepidopterología ·(unknown), Lyndell L. Lim, Constantine S. Tam	1
8	Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease 2023 ·Leukemia & lymphoma ·Thomas E. Lew, Edward R. Scheffer Cliff, Michael Dickinson, Constantine S. Tam, John F. Seymour, Piers Blombery, Ashish Bajel, David Ritchie, Amit Khot	5
9	Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts 2022 ·Clinical Cancer Research ·Paul M. Barr, Alessandra Tedeschi, William G. Wierda, John N. Allan, Paolo Ghia, Daniele Vallisa, Ryan Jacobs, Susan O’Brien, Andrew Grigg, Patricia Walker, Cathy Zhou, Joi Ninomoto, (unknown), Constantine S. Tam	6
10	Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial 2021 ·Clinical Cancer Research ·Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey Matous, D. Blair Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango‐Hisijara, Meletios Α. Dimopoulos	27
11	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study 2020 ·Clinical Cancer Research ·Matthew S. Davids, Bryone J. Kuss, Peter Hillmen, Marco Montillo, Carol Moreno, James Essell, Nicole Lamanna, Zsolt Nagy, Constantine S. Tam, Stephan Stilgenbauer, Paolo Ghia, Julio Delgado, Stephanie Lustgarten, David T. Weaver, Hagop Youssoufian, Ulrich Jäger	33
12	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months 2020 ·Blood Advances ·Thomas E. Lew, Mary Ann Anderson, Victor S. Lin, Sasanka M. Handunnetti, Neil Came, Piers Blombery, David Westerman, Meaghan Wall, Constantine S. Tam, Andrew W. Roberts, John F. Seymour	31
13	Zanubrutinib for the treatment of Waldenström Macroglobulinemia 2020 ·Expert Review of Hematology ·(unknown), Constantine S. Tam	3
14	Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) 2019 ·Blood ·Peter Hillmen, Jennifer R. Brown, John C. Byrd, Barbara Eichhorst, Nicole Lamanna, Susan O’Brien, Lugui Qiu, Tommi Salmi, James Hilger, Jane Huang, Constantine S. Tam	2
15	PF481 UPDATED SAFETY AND EFFICACY DATA IN A PHASE 1/2 TRIAL OF PATIENTS WITH WALDENSTRÖM MACROGLOBULINAEMIA (WM) TREATED WITH THE BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111) 2019 ·HemaSphere ·Judith Trotman, Stephen Opat, Paula Marlton, David Gottlieb, David Simpson, Gavin Cull, David Ritchie, Emma Verner, Javier Muñoz, Alessandra Tedeschi, Jennifer J. Huang, William Novotny, Medhat Osman, Siminder Atwal, John F. Seymour, Andrew W. Roberts, Constantine S. Tam	3
16	High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia – lessons for immunopathogenesis and prescribing 2019 ·Leukemia & lymphoma ·(unknown), Constantine S. Tam, Jim Siderov, John F. Seymour, Natasha E. Holmes, Kyra Chua, Elizabeth J. Phillips, Monica A. Slavin, Jason A. Trubiano	5
17	The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia 2019 ·Leukemia & lymphoma ·Masa Lasica, Abbey Willcox, Kate Burbury, David M. Ross, Susan Branford, Jason Butler, Robin Filshie, Henry Januszewicz, David Joske, Anthony K. Mills, David Simpson, Constantine S. Tam, Kerry Taylor, Anne-Marie Watson, Max Wolf, Andrew Grigg	15
18	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia breakdown → 2018 ·Cancer Discovery ·Piers Blombery, Mary Ann Anderson, Jianan Gong, Rachel Thijssen, Richard W. Birkinshaw, Ella R. Thompson, Charis E. Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E. Lew, Ian J. Majewski, Daniel H.D. Gray, David Westerman, Constantine S. Tam, John F. Seymour, Peter E. Czabotar, David C.S. Huang, Andrew W. Roberts	276
19	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism 2016 ·Blood ·Mary Ann Anderson, Jing Deng, John F. Seymour, Constantine S. Tam, Su Young Kim, Joshua Fein, Lijian Yu, Jennifer R. Brown, David Westerman, Éric Ghigo, Ian J. Majewski, David Segal, (unknown), David C.S. Huang, Matthew S. Davids, Anthony Letai, Andrew W. Roberts	215
20	De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience 2009 ·Blood ·Constantine S. Tam, Tait D. Shanafelt, William G. Wierda, Lynne V. Abruzzo, Daniel L. Van Dyke, Susan O’Brien, Alessandra Ferrajoli, Susan Lerner, Alice Lynn, Neil E. Kay, Michael J. Keating	114

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact